Gilead Sciences (NASDAQ:GILD) Releases FY 2026 Earnings Guidance

Gilead Sciences (NASDAQ:GILD) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 8.450-8.850 for the period, compared to the consensus earnings per share estimate of 8.690. The company issued revenue guidance of $29.6 billion-$30.0 billion, compared to the consensus revenue estimate of $30.1 billion.

Gilead Sciences Trading Down 2.9%

Gilead Sciences stock traded down $4.45 during midday trading on Tuesday, reaching $147.23. The stock had a trading volume of 10,737,165 shares, compared to its average volume of 7,852,057. The stock’s 50-day simple moving average is $127.92 and its 200 day simple moving average is $121.31. Gilead Sciences has a twelve month low of $93.37 and a twelve month high of $153.13. The company has a debt-to-equity ratio of 1.03, a quick ratio of 1.31 and a current ratio of 1.45. The stock has a market capitalization of $182.67 billion, a PE ratio of 22.83, a price-to-earnings-growth ratio of 0.80 and a beta of 0.36.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 10th. The biopharmaceutical company reported $1.86 EPS for the quarter, missing analysts’ consensus estimates of $1.87 by ($0.01). Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.Gilead Sciences has set its FY 2026 guidance at 8.450-8.850 EPS. Analysts expect that Gilead Sciences will post 7.95 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on GILD shares. UBS Group boosted their price objective on shares of Gilead Sciences from $145.00 to $155.00 and gave the stock a “buy” rating in a research note on Monday, January 26th. BMO Capital Markets upped their price target on shares of Gilead Sciences from $135.00 to $150.00 and gave the stock an “outperform” rating in a research report on Monday, January 26th. Argus increased their price target on Gilead Sciences from $130.00 to $135.00 and gave the company a “buy” rating in a report on Tuesday, November 4th. TD Cowen raised their price objective on Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a research report on Thursday, January 29th. Finally, Needham & Company LLC upped their target price on Gilead Sciences from $133.00 to $140.00 and gave the stock a “buy” rating in a research report on Thursday, November 13th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $136.73.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of Gilead Sciences stock in a transaction that occurred on Tuesday, January 20th. The stock was sold at an average price of $123.50, for a total transaction of $617,500.00. Following the sale, the director directly owned 8,920 shares in the company, valued at $1,101,620. The trade was a 35.92% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Daniel Patrick O’day sold 115,640 shares of the company’s stock in a transaction that occurred on Thursday, February 5th. The shares were sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the transaction, the chief executive officer directly owned 613,912 shares in the company, valued at approximately $92,086,800. The trade was a 15.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 373,037 shares of company stock valued at $50,731,512. Company insiders own 0.27% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Board raised the quarterly dividend by 3.8% to $0.82, supporting income investors and signaling confidence in cash flow. Gilead Sciences Announces 3.8 Percent Increase in First Quarter 2026 Dividend
• Positive Sentiment: Q4 results showed solid sales and profit performance with some outlets reporting beats or roughly inline with estimates, and management highlighted growth in liver disease and HIV products plus potential new cancer/HIV approvals this year. Gilead quarterly results beat Wall Street estimates Gilead Sciences Profit Rises on Growth of Liver Disease, HIV Products
• Neutral Sentiment: Some data items (short interest reporting) are effectively noise or inconsistent and don’t indicate a rising short-squeeze risk; treat with caution. (public short‑interest entry)
• Neutral Sentiment: Pre-earnings analyst previews and buy‑thesis pieces highlighted Yeztugo and the core portfolio as reasons for optimism, which supports medium‑term upside if launches and approvals execute. Gilead Q4 preview: Core portfolio, Yeztugo launch keep analysts optimistic ahead of earnings
• Negative Sentiment: Management set FY‑2026 EPS guidance at $8.45–8.85 and revenue guidance of $29.6–$30.0B, which sits at or below consensus estimates and drove the bulk of the sell‑off as it reduces near‑term upside expectations. Gilead Stock Slips After Q4 Earnings, Weak FY26 Guidance
• Negative Sentiment: Earnings per share results were reported as essentially flat/mixed versus estimates (variously characterized as a $0.01 miss or a small beat depending on the consensus used), reinforcing the view that guidance — not current results — is the key concern. Gilead Sciences (GILD) Surpasses Q4 Earnings and Revenue Estimates

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in GILD. Palisade Asset Management LLC acquired a new position in Gilead Sciences during the 3rd quarter valued at about $46,000. Wealth Watch Advisors INC acquired a new stake in shares of Gilead Sciences in the third quarter valued at approximately $60,000. Quantbot Technologies LP bought a new stake in shares of Gilead Sciences during the third quarter valued at approximately $72,000. Binnacle Investments Inc boosted its position in shares of Gilead Sciences by 14.3% during the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 88 shares during the period. Finally, Caitong International Asset Management Co. Ltd grew its holdings in Gilead Sciences by 135.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 713 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 410 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.